CD4 receptor localized to non-raft membrane microdomains supports HIV-1 entry. Identification of a novel raft localization marker in CD4.
Despite the preferential localization of CD4 to lipid rafts, the significance and role of these microdomains in HIV-1 entry is still controversial. The possibility that CD4, when localized to non-raft domains, might be able to support virus entry cannot be excluded. Because disintegration of rafts by extraction of cellular cholesterol with methyl-beta-cyclodextrin suffers from various adverse effects, we investigated molecular determinants controlling raft localization of the CD4 receptor. Extensive mutagenesis of the receptor showed that a raft-localizing marker, consisting of a short sequence of positively charged amino acid residues, RHRRR, was present in the membrane-proximal cytoplasmic domain of CD4. Substitution of the RHRRR sequence with alanine residues abolished raft localization of the CD4 mutant, RA5, as determined biochemically using solubilization in nonionic detergents and by confocal microscopy. The possible inhibitory effect of the introduced mutations on the adjacent CVRC palmitoylation site was ruled out because wild type (wt) CD4 and RA5, but not a palmitoylation-deficient mutant, were efficiently palmitoylated. Nonetheless, the RA5 mutant supported productive virus entry to levels equivalent to that of wild type (wt) CD4. Sucrose gradient analysis of Triton X-100 virus lysates showed that Gag and envelope gp120 proteins accumulated in low buoyant, high-density fractions. This pattern was changed after virus incubation with cells. Whereas Gag proteins localized to lipid rafts in cells expressing wt CD4 and RA5, gp120 accumulated in rafts in cells expressing wt CD4 but not RA5. We propose that raft localization of CD4 is not required for virus entry, however, post-binding fusion/entry steps may require lipid raft assembly.
Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA. wpopik@jhmi.edu
Waldemar
W
Popik
Timothy M
TM
Alce
D000595:Amino Acid Sequence; D001402:B-Lymphocytes / Q000276:immunology*; D001483:Base Sequence; D015704:CD4 Antigens / Q000032:analysis / Q000235:genetics / Q000276:immunology*; D002460:Cell Line; D002462:Cell Membrane / Q000276:immunology*; D002478:Cells, Cultured; D017931:DNA Primers; D006031:Glycosylation; D049452:Green Fluorescent Proteins; D015497:HIV-1 / Q000502:physiology*; D006801:Humans; D008164:Luminescent Proteins / Q000276:immunology; D021962:Membrane Microdomains / Q000276:immunology*; D009844:Oligosaccharides / Q000494:pharmacology; D019308:Palmitic Acid / Q000378:metabolism; D010446:Peptide Fragments / Q000737:chemistry; D015728:Receptors, HIV / Q000032:analysis; D011993:Recombinant Fusion Proteins / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*
C421467:3'-sialyllactose; D015704:CD4 Antigens; D017931:DNA Primers; D008164:Luminescent Proteins; D009844:Oligosaccharides; D010446:Peptide Fragments; D015728:Receptors, HIV; D011993:Recombinant Fusion Proteins; D049452:Green Fluorescent Proteins; D019308:Palmitic Acid